In relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL), 4-1BB-based CAR-T cells have been shown to show higher antitumor efficacy, longer persistence, and fewer serious adverse events than CD28 CAR-T cells (39). The gene discussed is CD28; the disease is B-cell acute lymphoblastic leukemia.